Audit: QRS - Semax for Health & Longevity

Audit conducted on 06/08/2026 19:12 using AI4L / Opus 5

Summary

Items	Count
Total	91
Passed	81
Failed	0
N/A	10
Pass Rate	100.00%

Total = Passed + Failed + N/A
Pass Rate = Passed / (Passed + Failed) x 100
N/A items are excluded from the pass rate calculation

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	Spot-checked every QRS claim against the ER: doses (200-600 ug, 100-500 ug NASA, 200-2,000 ug 0.1% solution), all 13 contraindications, all 17 interactions, all 10 biomarker targets and all 6 qualitative markers trace to explicit ER passages.
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	Cautious ER framing retained: “Practice-derived, not evidence-based”, “conflicted” markers on the two conflicted benefit/risk items, “unestablished” in At-A-Glance.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	No strengthening or softening detected; contraindication thresholds (90 days, 5 years, 4 weeks, 160/100 mmHg, HbA1c 8%, platelets 50 x 10^9/L, INR 3.0, eGFR 30) carried through unchanged.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Contraindications come only from the ER “Populations who should avoid Semax” list; Key Interactions only from the ER prescription/OTC/supplement/other interaction bullets. No Benefit- or Risk-Modifying Factor is surfaced as a gate.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	No PMIDs, study names, author names, NCT identifiers or brand names appear anywhere in the QRS.
1.6	The QRS does not introduce new attributions.	🟢	No attributions of any kind in the QRS.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Matches the ER register: measured, sceptical, evidence-graded.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Expert, objective and data-driven throughout; tier labels and thresholds give the reader the material to decide.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Presents graded evidence, not instructions.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	No clinical-advice phrasing; footer disclaimer unchanged from the template.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	No “should”, “must”, “recommend”, “advise”, “consider” or “ensure” anywhere in the document (verified by search).
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person pronouns anywhere in the document (verified by search).
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Acronyms expanded on the sheet (hs-CRP, BDNF, ACTH, INR); “BDNF protein” in the ER rendered as “Brain-derived neurotrophic factor protein” in time_2_sub.
2.8	Information is presented in a concise and very compact manner	🟢	Every card entry is a terse phrase or clause; no prose paragraphs outside the protocol sub-cells.
2.9	It DOES NOT address the reader directly	🟢	Confirmed - no direct address.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Framed for elective optimisation use (“Longevity and nootropic protocol”), with gray-market sourcing risk surfaced at High.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Assumes willingness to run defined courses, split dosing, nostril rotation and a 10-marker baseline panel.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	Not general-population framing; assumes lab access and protocol adherence.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	At-A-Glance carries the ER conclusion that lasting gains in healthy adults are unestablished - the signal specific to this audience.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	No occurrence of “anti-aging” in the document.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt.	🟢	Formal register throughout (“intranasally”, “oral administration”, “adverse” concepts named clinically); no consumer-grade substitutes.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: • Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment” • Gate headings: “Contraindications”, “Key Interactions” • Tier labels: “High”, “Medium”, “Low”, “Speculative” • Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All fixed headings present verbatim: Protocol, Time to effect, Benefits, Risk & Side Effects, Monitoring, Qualitative Assessment, Contraindications, Key Interactions; tiers High/Medium/Low/Speculative; table headers Marker/Target/Why.
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	All 34 template spans present; marker_#* and qualitative_item# expanded to marker_1..10 and qualitative_item_1..6 as the template indexing intends.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	Structural diff against [qrs_template] shows only variable-region content changes plus the indexed row/li repetitions; CSS, comments, footer disclaimer and subline boilerplate are byte-identical.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No source ER section used by the QRS is empty, so no empty-state phrasing applies.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	ER bold labels reused: “Route selection”, “Best time of day”, “Longevity and nootropic protocol”; all 10 monitoring row labels and all 6 qualitative bold labels are the ER labels verbatim.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	Time-to-effect labels (“Acute pharmacodynamic effects”, “Neurotrophin elevation”, “Clinical or cumulative effects”) are lifted verbatim from the ER “Time to effect” bullet, not invented.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	No emoji anywhere in the document (verified by search); the ER “Conflicted” flags are carried as the plain word “conflicted”.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Every section is condensed relative to the ER rather than extended; the sheet is long because sections 8.2, 9.2, 14.2 and 15.2 mandate complete coverage of an ER with 13 contraindications, 17 interactions and 10 biomarkers, and each item is already reduced to its key fact.

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Metadata comment is the first element after <!doctype html>, before <html>.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	YAML delimited by “—” lines inside the comment; the “QRS - Metadata” preamble line precedes the opening “—”.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	Inside an HTML comment; not rendered and not duplicated anywhere on the sheet.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	All values trimmed; only “00:04” is quoted, which is required because it contains a colon.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	er_filename: semax_2026-0806-1441_Opus_ER.md
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	qrs_prompt_version: 26.7.02, matching the QRS.md version badge.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	qrs_creation_date: 2026-0806-1850
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	qrs_creator_ai_nickname: Opus
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	Single word, no version.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	qrs_creator_ai_fullname: Opus 5
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	Nickname plus version number, no qualifier.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	qrs_filename: semax_2026-0806-1441_Opus_QRS.html
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Confirmed clean; the additional duration/git_user/git_issue keys follow the same convention.

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER `frontmatter` followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., `&` for `&`)	🟢	The page title reads “Semax for Health & Longevity - Quick Reference Sheet”, with the ampersand entity-encoded.
6.2	[header_topic] is set to the [canonical_topic] of the ER `frontmatter`, with HTML entities encoded as needed (e.g., `&` for `&`)	🟢	header_topic: “Semax for Health & Longevity”.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	header_subline_date: 08/06/2026, matching qrs_creation_date 2026-0806.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	header_subline_model: Opus 5.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	Subline is byte-identical to the template apart from the two variables; no badge, AKA line, version stamp or audit date.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER `Conclusion` section	🟢	Distils the ER Conclusion into five clauses covering regulatory standing, evidence asymmetry, acute effect, unestablished healthy-adult benefit, conflict of interest, and safety/supply.
7.2	[at_a_glance] is no longer than 60 words	🟢	58 words.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Each clause maps to a distinct Conclusion sentence (Russian prescription use; large laboratory/animal body; imaging within minutes; unestablished lasting gains; developer-dominated stroke record; unstudied long-term safety and unregulated supply).
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	Plain language throughout; no acronyms and no clinical-register terms requiring specialist knowledge.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	No trial names, years, sample sizes or p-values.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	No effect sizes, relative risks or statistics.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER `Key Interactions & Contraindications` section	🟢	Derived from the ER “Populations who should avoid Semax” subsection of Key Interactions & Contraindications.
8.2	[stop_items] represent the Contraindications from the ER	🟢	All 13 ER avoid-list entries are present, in ER order.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	13 <li> elements inside the stop_items span.
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	All ER trailing rationale clauses stripped (“- absolute contraindication; no reproductive toxicity data exist…”, “- avoid, on monoaminergic activation”, etc.).
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Qualifiers preserved: within 90 days, 50 x 10^9/L, INR 3.0, 160/100 mmHg, HbA1c 8%, past 5 years, nasal surgery within 4 weeks, eGFR below 30 mL/min/1.73 m^2.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER contraindication list uses no ranking notation inside parentheses.
8.7	If no [stop_items] are present the section is left empty	N/A	stop_items are present.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER `Key Interactions & Contraindications` section	🟢	Derived from the ER prescription, over-the-counter, supplement and other-intervention interaction bullets.
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	All 17 restrictive ER interactions are present; none duplicates a contraindication. The ER “Aerobic and high-intensity exercise” bullet is explicitly “no restriction” and is correctly not surfaced in a caution gate.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	17 <li> elements inside the caution_items span.
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	All ER mechanism, clinical-consequence and mitigation text stripped; only the drug class and its example list remain.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Example drug lists preserved and trimmed for budget (e.g. dextroamphetamine, rivaroxaban, dabigatran, indapamide, S-adenosylmethionine dropped from otherwise intact lists), never dropped entirely.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER interaction list uses no ranking notation inside parentheses.
9.7	If no [caution_items] are present the section is left empty	N/A	caution_items are present.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER `Protocol` section	🟢	Derived from the ER Therapeutic Protocol section.
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER `Protocol` section	🟢	Dose/regimen, route, and timing - the three aspects a reader must settle before use; the ER protocol bullets on genetics, sex and age are explicitly non-actionable in the ER itself.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	Three distinct actionable aspects exist and all three sets are used.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER `Protocol` section.	🟢	All nine action_* variables carry ER-derived content (200-600 ug intranasally; intranasal route with the oral/subcutaneous caveats; morning with a second dose no later than early afternoon).

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	The ER “Time to effect” bullet names exactly three timescales and all three are carried.
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	time_1 is the acute pharmacodynamic effect tied to the sole High-tier benefit; time_2 and time_3 are both tied to Medium-tier benefits (BDNF elevation, stroke recovery).
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	Three distinct time-to-effect aspects exist and all three sets are used.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	All nine time_* variables carry ER-derived content (5-20 minutes; about 3 hours; 10-14 day courses).
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the `Protocol Panel`	N/A	The ER does provide time-to-effect information, so the section is retained.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER `Expected Benefits` section	🟢	Derived from the ER Expected Benefits section.
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four variables populated.
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Every entry is the ER benefit heading reduced to a clause; no magnitudes, mechanisms or citations.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parenthetical content anywhere in the benefits card.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four tiers have items in the ER.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER `Potential Risks & Side Effects` section	🟢	Derived from the ER Potential Risks & Side Effects section.
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four variables populated.
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Every entry is the ER risk heading reduced to a clause; the 10% and 7.4% frequencies and all mechanism text are omitted.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parenthetical content anywhere in the risks card.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four tiers have items in the ER.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER `Monitoring` section	🟢	Derived from the ER Monitoring Protocol & Defining Success table.
14.2	All measurable/quantifiable biomarkers from the `Monitoring` section are listed	🟢	All 10 ER biomarkers present with targets verbatim: blood pressure, hs-CRP, serum BDNF, morning cortisol, ACTH, fasting glucose, homocysteine, INR, platelet count, serum copper and ceruloplasmin.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER `Monitoring` section. It is not left with placeholder text or empty.	🟢	monitoring_cadence reproduces the ER cadence paragraph verbatim.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER `Monitoring` section	🟢	Derived from the qualitative-marker list in the ER Monitoring Protocol & Defining Success section.
15.2	All subjective/qualitative biomarkers from the `Monitoring` section are listed	🟢	All 6 ER qualitative markers present with their bold labels verbatim.

Issues 06/08/2026 19:12

Pass rate 100.00%. No issues found.

Issues 06/08/2026 19:02

10.4 — Out-of-scope Protocol sub-cell content: [action_3_sub] ends with “All dosing before 14:00 and at least 6 hours before intended sleep”, which is drawn from the ER Risk Mitigation Strategies section (ER line 440) rather than the Protocol section that item 10.4 scopes to, while the Protocol section’s own pre-task dosing detail (ER line 467) goes unused.

Fixes 06/08/2026 19:02

10.4 — Protocol sub-cell resourced from Protocol section: Replaced the closing sentence of [action_3_sub], “All dosing before 14:00 and at least 6 hours before intended sleep” (drawn from the ER Risk Mitigation Strategies section), with the Protocol section’s own pre-task dosing detail: “Where the intent is cognitive performance on a specific task, dosing 15–30 minutes beforehand matches the 5-to-20-minute onset.”

Issues 06/08/2026 18:56

4.5 — Six unclosed pcell divs break layout: The </div> closing each div.pcell is missing after the action_1_sub, action_2_sub, action_3_sub, time_1_sub, time_2_sub, and time_3_sub cells (lines 461, 476, 490, 509, 522, 535), so each following .pcell nests inside the previous one and the two three-column .protocol-grid rows collapse instead of rendering within the one-page A4 layout.

Fixes 06/08/2026 18:56

4.5 — Closed six unclosed pcell divs: Added the missing </div> closing each div.pcell after the action_1_sub, action_2_sub, action_3_sub, time_1_sub, time_2_sub, and time_3_sub cells, restoring the two three-column .protocol-grid rows to the template’s structure.